[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

De Clercq, 2015 - Google Patents

Current treatment of hepatitis B virus infections

De Clercq, 2015

Document ID
3256869650357182958
Author
De Clercq E
Publication year
Publication venue
Reviews in Medical Virology

External Links

Snippet

Chronic hepatitis B virus (HBV) infection remains an important global burden with an estimated 240 million HBV carriers worldwide and more than half a million people dying annually from the consequences of the HBV infection. Besides interferon and pegylated …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse Transcribing DNA Viruses
    • C12N2730/00011—Reverse Transcribing DNA Viruses
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
De Clercq Current treatment of hepatitis B virus infections
Naggie et al. New therapeutics for hepatitis B: the road to cure
Asselah et al. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure
Bazinet et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
Lok Prevention of hepatitis B virus–related hepatocellular carcinoma
Gish et al. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities
Westland et al. Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients
Papatheodoridis et al. Diagnosis and management of pre‐core mutant chronic hepatitis B
Wang et al. Gender disparity in chronic hepatitis B: mechanisms of sex hormones
Ocama et al. Hepatitis B virus infection: current status
Chang et al. Systematic review: cessation of long‐term nucleos (t) ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B
Lok Hepatitis B infection: pathogenesis and management
Zoulim et al. Reasons to consider earlier treatment of chronic HBV infections
Jonas et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options
Gish et al. Selection of chronic hepatitis B therapy with high barrier to resistance
Wong et al. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B
Suk‐Fong Lok Hepatitis B: 50 years after the discovery of Australia antigen
Wang et al. Recent developments in antivirals against hepatitis B virus
Feld et al. New perspectives on development of curative strategies for chronic hepatitis B
Jeng et al. What will it take to cure hepatitis B?
Nishida et al. A prospective and comparative cohort study on efficacy and drug resistance during long‐term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis
Russo et al. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease
Coppola et al. Tolerability and efficacy of anti‐HBV nucleos (t) ide analogues in HBV‐DNA‐positive cirrhotic patients with HBV/HCV dual infection
Manne et al. Current perspectives into the evaluation and management of hepatitis B: a review
Stein et al. Drug targets in hepatitis B virus infection